CLAIMS

1. A solid pharmaceutical formulation suitable for oral administration comprising:

(a) an active agent which is S-pindolol or a pharmaceutically acceptable salt thereof;

(b) a starch excipient in an amount of at least 15.0 % by weight relative to the total weight of the formulation; and

(c) a cellulose excipient in an amount of at least 30.0 % by weight relative to the total weight of the formulation.

2. A solid pharmaceutical formulation according to claim 1, which solid pharmaceutical composition comprises:

(a) an active agent which is S-pindolol or a pharmaceutically acceptable salt thereof;

(b) a starch excipient in an amount of at least 15.0 % by weight relative to the total weight of the formulation; and

(c) a cellulose excipient in an amount of at least 40.0 % by weight relative to the total weight of the formulation.

3. A solid pharmaceutical formulation according to claim 1 or claim 2, wherein the active agent is a pharmaceutically acceptable salt of S-pindolol.

4. A solid pharmaceutical formulation according to any one of the preceding claims, wherein the active agent is a pharmaceutically acceptable salt of (i) S-pindolol and (ii) an organic acid, which organic acid has: a pK_{a1} of greater than or equal to 2.5; and a chemical formula of $C_xH_y(CO_2H)_z$, where x is from 1 to 10, y is from 2 to 20 and z is 1 or 2,

preferably wherein the organic acid is benzoic acid, succinic acid, fumaric acid, malonic acid, glutaric acid, adipic acid, acetic acid, propionic acid, phenylacetic acid, toluic acid or naphthoic acid.

5. A solid pharmaceutical formulation according to any one of the preceding claims, wherein the active agent is S-pindolol benzoate.

6. A solid pharmaceutical formulation according to any one of the preceding claims, wherein the active agent is present in an amount of from 1.0 to 25.0 % by weight relative to the total weight of the formulation,

preferably wherein the active agent is present in an amount from 10.0 to 20.0 % by weight relative to the total weight of the formulation.

7. A solid pharmaceutical formulation according to any one of the preceding claims, wherein the starch excipient is present in an amount of at least 20.0 % by weight relative to the total weight of the formulation,

preferably wherein the starch excipient is present in an amount of from 25.0 to 35.0 % by weight relative to the total weight of the formulation.

8. A solid pharmaceutical formulation according to any one of the preceding claims, wherein the starch excipient comprises starch,

preferably wherein the starch excipient comprises one or more of maize starch, wheat starch, rice starch, cassava starch and cocoyam starch,

more preferably wherein the starch excipient comprises maize starch.

9. A solid pharmaceutical formulation according to any one of the preceding claims, wherein the starch excipient comprises a starch which is at least partially pregelatinized.

10. A solid pharmaceutical formulation according to any one of the preceding claims, wherein the cellulose excipient is present in an amount of at least 45.0 % by weight relative to the total weight of the formulation,

preferably wherein the cellulose excipient is present in an amount of from 50.0 to 60.0 % by weight relative to the total weight of the formulation.

11. A solid pharmaceutical formulation according to any one of the preceding claims, wherein the cellulose excipient comprises microcrystalline cellulose.

12. A solid pharmaceutical formulation according to any one of the preceding claims, wherein the solid pharmaceutical formulation comprises: a starch excipient which is starch; and a cellulose excipient which is microcrystalline cellulose.

13. A solid pharmaceutical formulation according to any one of the preceding claims, wherein the solid pharmaceutical formulation further comprises colloidal silica,

optionally wherein the colloidal silica is present in an amount of from 0.1 to 1.0 % by weight relative to the total weight of the formulation.

14. A solid pharmaceutical formulation according to any one of the preceding claims, wherein the solid pharmaceutical formulation further comprises a lubricant, preferably wherein the lubricant is magnesium stearate,

optionally wherein the lubricant is present in an amount of from 0.1 to 1.0 % by weight relative to the total weight of the formulation.

15. A solid pharmaceutical formulation according to any one of the preceding claims, wherein the solid pharmaceutical formulation comprises less than 10.0 % by weight of lactose relative to the total weight of the formulation,

preferably wherein the solid pharmaceutical formulation comprises less than 1.0 % by weight of lactose.

16. A solid pharmaceutical formulation according to any one of the preceding claims, wherein the solid pharmaceutical formulation comprises:

(a) 5.0 to 25.0 % by weight of a pharmaceutically acceptable salt of S-pindolol as defined in claim 3 or 4;

(b) at least 20.0 % by weight of a starch excipient as defined in claim 7 or claim 8; and

(c) at least 45.0 % by weight of a cellulose excipient as defined in claim 10,

wherein the % by weight is relative to the total weight of the formulation.

17. A solid pharmaceutical formulation according to any one of the preceding claims,

wherein the solid pharmaceutical formulation comprises:

(a) 10 to 20 % by weight of S-pindolol benzoate;

(b) 20 to 30 % by weight of starch;

(c) 50 to 60 % by weight of microcrystalline cellulose;

(d) optionally colloidal silica; and

(e) optionally magnesium stearate,

wherein the % by weight is relative to the total weight of the formulation.

18. A solid pharmaceutical formulation according to any one of the preceding claims, wherein the solid pharmaceutical formulation is a tablet.

19. A solid pharmaceutical formulation according to any one of the preceding claims, wherein the solid pharmaceutical formulation is a tablet comprising:

(a) 10 to 20 % by weight of S-pindolol benzoate;

(b) 22 to 30 % by weight of maize starch, which maize starch is preferably partially pregelatinized;

(c) 50 to 60 % by weight of microcrystalline cellulose;

(d) 0.1 to 0.5 % by weight of colloidal silica; and

(e) 0.1 to 0.5 % by weight of magnesium stearate,

wherein the % by weight is relative to the total weight of the formulation.

20. Use of a solid pharmaceutical formulation as defined in any one of claims 1 to 19 in the manufacture of a medicament for the treatment or prevention of a disease or condition selected from cachexia, sarcopenia, a neuromuscular disorder, muscle weakness, hypertension, heart failure, atrial fibrillation, heart attack, angina pectoris, glaucoma and anxiety.

21. Use according to claim 20, wherein the disease or condition is cachexia or muscle weakness.